The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Open accessAbstract
The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based particle vaccine, RTS,S, which targets the pre-erythrocytic stage of Plasmodium falciparum infection. It induces modest levels of protective efficacy, thought to be mediated primarily by CSP-specific antibodies. We aimed to enhance vaccine efficacy by generating a more immunogenic CSP-based particle vaccine and therefore developed a next-generation RTS,S-like vaccine, called R21. The major improvement is that in contrast to RTS,S, R21 particles are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and this leads to a vaccine composed of a much higher proportion of CSP than in RTS,S. We demonstrate that in BALB/c mice R21 is immunogenic at very low doses and when administered with the adjuvants Abisco-100 and Matrix-M it elicits sterile protection against transgenic sporozoite challenge. Concurrent induction of potent cellular and humoral immune responses was also achieved by combining R21 with TRAP-based viral vectors and protective efficacy was significantly enhanced. In addition, in contrast to RTS,S, only a minimal antibody response to the HBsAg carrier was induced. These studies identify an anti-sporozoite vaccine component that may improve upon the current leading malaria vaccine RTS,S. R21 is now under evaluation in Phase 1/2a clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Ahmad, M., Hirz, M., Pichler, H., & Schwab, H. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5732-5 · Cited by 989
Recombinant protein expression in Pichia pastoris
Cregg, J. M., Cereghino, J. L., Shi, J., & Higgins, D. R. (2000) · Molecular Biotechnology · doi:10.1385/mb:16:1:23 · Cited by 927
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
The Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 717
Hoffman, S. L., Goh, L. M. L., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., Sacci, J., de la Vega, P., Dowler, M., Paul, C., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/339409 · Cited by 688
Bache, E. B., Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Kabwende, A. L., Adégnika, A. A., Mordmüller, B. G., Kremsner, P. G., Loembé, M. M., et al. (2015) · The Lancet · doi:10.15496/publikation-6508 · Cited by 642
Protection against a Malaria Challenge by Sporozoite Inoculation
Roestenberg, M., McCall, M., Hopman, J., Wiersma, J., Luty, A. J. F., van Gemert, G. J., van de Vegte-Bolmer, M., van Schaijk, B., Teelen, K., Arens, T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805832 · Cited by 577
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
The RTS, S. C. T. P. (. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001685 · Cited by 474
NEUTRALIZING ANTIVIRAL B CELL RESPONSES
Bachmann, M. F., & Zinkernagel, R. M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.235 · Cited by 471
T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells
Kedl, R. M., Rees, W. A., Hildeman, D. A., Schaefer, B., Mitchell, T., Kappler, J., & Marrack, P. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1105 · Cited by 406
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
Ishizuka, A. S., Lyke, K. E., DeZure, A., Berry, A. A., Richie, T. L., Mendoza, F. H., Enama, M. E., Gordon, I. J., Chang, L.-J., Sarwar, U. N., et al. (2016) · Nature Medicine · doi:10.1038/nm.4110 · Cited by 367
Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1576 · Cited by 327
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Ewer, K. J., O’Hara, G. A., Duncan, C. J. A., Collins, K. A., Sheehy, S. H., Reyes-Sandoval, A., Goodman, A. L., Edwards, N. J., Elias, S. C., Halstead, F. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3836 · Cited by 286
Self-citationFrom malaria control to eradication: The WHO perspective
Mendis, K., Rietveld, A., Warsame, M., Bosman, A., Greenwood, B., & Wernsdorfer, W. H. (2009) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2009.02287.x · Cited by 277
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
O’Hara, G. A., Duncan, C. J. A., Ewer, K. J., Collins, K. A., Elias, S. C., Halstead, F. D., Goodman, A. L., Edwards, N. J., Reyes-Sandoval, A., Bird, P., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir850 · Cited by 214
Self-citationSheehy, S. H., Duncan, C. J., Elias, S. C., Choudhary, P., Biswas, S., Halstead, F. D., Collins, K. A., Edwards, N. J., Douglas, A. D., Anagnostou, N. A., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.223 · Cited by 212
Self-citationCharacterization of Plasmodium falciparum sporozoite surface protein 2.
Rogers, W. O., Malik, A., Mellouk, S., Nakamura, K., Rogers, M. D., Szarfman, A., Gordon, D. M., Nussler, A. K., Aikawa, M., & Hoffman, S. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9176 · Cited by 207
Immunogenicity of Synthetic Peptides from Circumsporozoite Protein of Plasmodium falciparum
Ballou, W. R., Rothbard, J., Wirtz, R. A., Gordon, D. M., Williams, J. S., Gore, R. W., Schneider, I., Hollingdale, M. R., Beaudoin, R. L., Maloy, W. L., et al. (1985) · Science · doi:10.1126/science.2988126 · Cited by 200
Prime-boost vectored malaria vaccines: Progress and prospects
Hill, A. V. S., Reyes-Sandoval, A., O’Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A., Folgori, A., Colloca, S., Cortese, R., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.1.10116 · Cited by 193
Self-citationHEPPNERJR, D., KESTER, K., OCKENHOUSE, C., TORNIEPORTH, N., OFORI, O., LYON, J., STEWART, V, DUBOIS, P., LANAR, D., & KRZYCH, U. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.142 · Cited by 192
White, M. T., Bejon, P., Olotu, A., Griffin, J. T., Riley, E. M., Kester, K. E., Ockenhouse, C. F., & Ghani, A. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061395 · Cited by 184
Reyes-Sandoval, A., Berthoud, T., Alder, N., Siani, L., Gilbert, S. C., Nicosia, A., Colloca, S., Cortese, R., & Hill, A. V. S. (2010) · Infection and Immunity · doi:10.1128/iai.00740-09 · Cited by 176
Self-citationA protein particle vaccine containing multiple malaria epitopes
Gilbert, S. C., Plebanski, M., Harris, S. J., Allsopp, C. E. M., Thomas, R., Layton, G. T., & Hill, A. V. S. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1280 · Cited by 147
Self-citationOgwang, C., Kimani, D., Edwards, N. J., Roberts, R., Mwacharo, J. K., Bowyer, G., Bliss, C. M., Hodgson, S. H. C., Njuguna, P., Viebig, N. K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2373 · Cited by 129
Self-citationImmunological mechanisms underlying protection mediated by RTS,S: a review of the available data
Moorthy, V., & Ballou, W. R. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-312 · Cited by 125
John, C. C., Moormann, A. M., Pregibon, D. C., Sumba, P. O., MCHUGH, M. M., Narum, D. L., Lanar, D. E., SCHLUCHTER, M. D., & Kazura, J. W. (2005) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.222 · Cited by 122
CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria
Reyes‐Sandoval, A., Wyllie, D. H., Bauza, K., Milicic, A., Forbes, E. K., Rollier, C. S., & Hill, A. V. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100302 · Cited by 121
Self-citationKaba, S. A., McCoy, M. E., Doll, T. A. P. F., Brando, C., Guo, Q., Dasgupta, D., Yang, Y., Mittelholzer, C., Spaccapelo, R., Crisanti, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048304 · Cited by 120
Gantt, S. M., Persson, C., Rose, K., Birkett, A. J., Abagyan, R. A., & Nussenzweig, V. (2000) · Infection and Immunity · doi:10.1128/iai.68.6.3667-3673.2000 · Cited by 110
The RTS,S vaccine candidate for malaria
Regules, J. A., Cummings, J. F., & Ockenhouse, C. F. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.57 · Cited by 100
Rampling, T., Ewer, K., Bowyer, G., Bliss, C. M., Edwards, N. J., Wright, D., Payne, R., Venkatraman, N., de Barra, E., Snudden, C. M., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw244 · Cited by 99
Self-citationSpecific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides
Roos, A., Nauta, A. J., Broers, D., Faber‐Krol, M. C., Trouw, L. A., Drijfhout, J. W., & Daha, M. R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.12.7052 · Cited by 95
Lumsden, J. M., Schwenk, R., Rein, L., Moris, P., Janssens, M., Ofori‐Anyinam, O., Cohen, J., Kester, K. E., Heppner, D. G., & Krzych, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020775 · Cited by 87
Ogwang, C., Afolabi, M. O., Kimani, D., Jagne, Y. J., Hodgson, S. H. C., Bliss, C. M., Duncan, C. J. A., Collins, K. A., Garcia-Knight, M., Kimani, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057726 · Cited by 87
Self-citationReduced immunogenicity of DNA vaccine plasmids in mixtures
Sedegah, M., Charoenvit, Y., Minh, L. Q., Belmonte, M., Majam, V., Abot, S., Ganeshan, H. D., Kumar, S., Bacon, D., Stowers, A. W., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302139 · Cited by 83
Capone, S., Reyes‐Sandoval, A., Naddeo, M., Siani, L., Ammendola, V., Rollier, C. S., Nicosia, A., Colloca, S., Cortese, R., Folgori, A., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.041 · Cited by 79
Self-citationKastenmüller, K., Espinosa, D. A., Trager, L., Stoyanov, C. T., Salazar, A. Μ., Pokalwar, S., Singh, S. P., Dutta, S., Ockenhouse, C. F., Zavala, F. P., et al. (2012) · Infection and Immunity · doi:10.1128/iai.01108-12 · Cited by 78
What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines
Penny, M. A., Maire, N., Studer, A., Schapira, A., & Smith, T. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003193 · Cited by 75
Leach, A. J., Vekemans, J., Lievens, M., Ofori‐Anyinam, O., Cahill, C. P., Owusu‐Agyei, S., Abdulla, S., Macete, E., Njuguna, P., Savarese, B., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-224 · Cited by 75
Bastiaens, G. J. H., van Meer, M. P. A., Scholzen, A., Obiero, J. M., Vatanshenassan, M., van Grinsven, T., Sim, B. K. L., Billingsley, P. F., James, E. R., Gunasekera, A. M., et al. (2015) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.15-0621 · Cited by 72
Genetic engineering of attenuated malaria parasites for vaccination
Khan, S. M., Janse, C. J., Kappe, S. H. I., & Mikolajczak, S. A. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.04.003 · Cited by 62
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
Warimwe, G. M., Lorenzo, G., López-Gil, E., Reyes‐Sandoval, A., Cottingham, M. G., Spencer, A. J., Collins, K. A., Dicks, M. D. J., Milicic, A., Lall, A., et al. (2013) · Virology Journal · doi:10.1186/1743-422x-10-349 · Cited by 61
Self-citationSafety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
Afolabi, M. O., Tiono, A. B., Adetifa, U. J., Yaro, J. B., Drammeh, A., Nébié, I., Bliss, C. M., Hodgson, S. H. C., Anagnostou, N. A., Sanou, G. S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.83 · Cited by 61
Self-citationJohn, C. C., Zickafoose, J. S., Sumba, P. O., King, C. L., & Kazura, J. W. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4320-4325.2003 · Cited by 60
McCoy, M. E., Golden, H. E., Doll, T. A. P. F., Yang, Y., Kaba, S. A., Burkhard, P., & Lanar, D. E. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-136 · Cited by 56
Kimani, D., Jagne, Y. J., Cox, M., Kimani, E. N., Bliss, C. M., Gitau, E., Ogwang, C., Afolabi, M. O., Bowyer, G., Collins, K. A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.109 · Cited by 54
Self-citationClinical Development of RTS,S/AS Malaria Vaccine: A Systematic Review of Clinical Phase I–III Trials
Agnandji, S. T., Fernandes, J. F., Bache, E. B., & Ramharter, M. (2015) · Future Microbiology · doi:10.2217/fmb.15.90 · Cited by 54
Aíde, P., Dobaño, C., Sacarlal, J., Aponte, J. J., Mandomando, I., Guinovart, C., Bassat, Q., Renom, M., Puyol, L., Macete, E., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.03.041 · Cited by 50
Ndungu, F. M., Mwacharo, J. K., Kimani, D., Kai, O. K., Moris, P., Jongert, E., Vekemans, J., Olotu, A., & Bejon, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052870 · Cited by 46
Hutchings, C. L., Birkett, A. J., Moore, A., & Hill, A. V. S. (2007) · Infection and Immunity · doi:10.1128/iai.00828-07 · Cited by 46
Self-citationForbes, E. K., Biswas, S., Collins, K. A., Gilbert, S. C., Hill, A. V. S., & Draper, S. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003783 · Cited by 41
Self-citationPichyangkul, S., Tongtawe, P., Kum-Arb, U., Yongvanitchit, K., Gettayacamin, M., Hollingdale, M. R., Limsalakpetch, A., Stewart, V. A., Lanar, D. E., Dutta, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.022 · Cited by 37
The whole parasite, pre-erythrocytic stage approach to malaria vaccine development
Epstein, J. E., & Richie, T. L. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000002 · Cited by 34
Dey, A., Burke, B., Sun, Y., Hartog, K., Heeney, J. L., Montefiori, D. C., Srivastava, I. K., & Barnett, S. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.027 · Cited by 23
Tailoring a Combination Preerythrocytic Malaria Vaccine
Bauza, K., Atcheson, E., Malinauskas, T., Blagborough, A. M., & Reyes‐Sandoval, A. (2015) · Infection and Immunity · doi:10.1128/iai.01063-15 · Cited by 20
Cited by
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
RTS,S/AS01 vaccine (Mosquirix™): an overview
Laurens, M. B. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1669415 · Cited by 491
Datoo, M. S., Natama, M. H., Somé, A., Traoré, O., Rouamba, T., Bellamy, D., Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00943-0 · Cited by 452
Self-citationMarcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 448
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Metadata
- Authors
- Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C., & Hill, A. V. S.
- Venue
- Scientific Reports
- Published
- 2017-04-19
- Volume
- 7
- Issue
- 1
- Pages
- 46621-46621
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2605491919
- Cited by
- 253
- References
- 60
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.